SAN FRANCISCO, CA / ACCESSWIRE / October 8, 2020 / Teon Therapeutics, Inc. has been invited to present at the Fall Private Company Showcase hosted by Solebury Trout, BMO and Davis Polk which is being held virtually on October 15, 2020.
Teon is scheduled to present on October 15 at 11:40am PT, with one-on-one meetings to be held throughout the conference. The presentation will be webcast live and available for replay: https://www.webcaster4.com/Webcast/Page/2408/37746
To receive additional information, request an invitation or to schedule a one-on-one meeting, please email info@teonthera.com
About Teon:
Teon Therapeutics is a private biopharma start-up developing a portfolio of small molecules that modulate metabolic signaling pathways in the tumor microenvironment. Teon’s lead program is first-in-class A2BR-specific antagonist that will enter Phase 1b trials in 2021. Our experienced leadership team are experts in adenosine and GPCR therapeutics and were primary inventors of Lexiscan and Ranexa, which led to the acquisition of CV Therapeutics by Gilead.
Contact:
SOURCE: Teon Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/609721/Teon-Therapeutics-to-Present-at-Solebury-Trout-Private-Company-Showcase-on-October-15-2020
CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…
Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…
Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…
Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…
Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a…